CTRL Therapeutics has filed a notice of an exempt offering of securities to raise $10,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CTRL Therapeutics is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management President, Shana Kelley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CTRL Therapeutics
CTRL Therapeutics is working to disrupt and democratize the cell therapy space and enable the rapid generation of potent anti-tumor T cell repertoires from every patient with cancer. We are building a company culture based on collaboration, transparency, integrity, and commitment to excellence. We are looking for passionate people to join us on our journey and build a world-class organization.
To learn more about CTRL Therapeutics, visit http://www.ctrl-therapeutics.com/
Contact:
Shana Kelley, President
415-283-5794
https://www.linkedin.com/in/shana-kelley-0346ab21/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.